ReviewCureus2025
Outcomes and Complications of Brainstem Arteriovenous Malformation (AVM) Embolization: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brainstem arteriovenous malformations (AVMs) are rare, high-risk lesions with controversial endovascular management. We systematically reviewed the literature to clarify obliteration rates, complications, and mortality related to embolization of intrinsic brainstem AVMs and to situate the technique within modern multimodal care. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidance, PubMed and Scopus were searched without date limits using combined terms related to brainstem structures (midbrain, pons, medulla oblongata), arteriovenous malformations, and embolization. Original English-language reports that provided detailed clinical or radiographic outcomes after endovascular treatment were eligible. Two reviewers independently screened records, extracted data, and assessed quality with ROBINS-I or CARE. Due to heterogeneity, results were summarized descriptively. Nine studies (aged 13-79 years) met the criteria. Hemorrhage was the initial presenting event in 62%, followed by cranial nerve or long-tract deficits. Embolic agents used included n-butyl-cyanoacrylate, Onyx, glue, and coils; most lesions were treated in one (60%) or two sessions. Reported nidus obliteration ranged from 23% to 100%; complete angiographic cure was achieved in all patients in three small series that employed either the Pressure-Cooker Technique or adjunctive microsurgery/radiosurgery. Procedure-related morbidity included new neurological deficits (up to 24%), infarction (7%), and rebleed (10%). The 30-day mortality ranged from 0% to 5% across series. Median follow-up was 12 months (range 1-48), with a few late hemorrhages. Endovascular embolization can achieve meaningful flow reduction and, in selected cases, complete obliteration of brainstem AVMs, but success and safety vary widely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.